Evidence map›Paper›PMID 41530814›Full record

ArticleBMC veterinary research2026

Evaluation of a P48 ELISA for Mycoplasmopsis (Mycoplasma) bovis in North American bison (Bison bison): inferior performance compared to a commercially available ELISA.

Catherine B Krus, Mary Nehring, Bryan S Kaplan, Christie Mayo, Courtney Maichak, Lee Jones, Sue VandeWoude, Danielle E Buttke

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Catherine B KrusDepartment of Clinical Sciences, College of Veterinary Medicine, Colorado State University, Ft. Collins, CO, 80523, USA.
Mary NehringDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA.
Bryan S KaplanRuminant Diseases and Immunology Research Unit, National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture, Ames, IA, USA.
Christie MayoDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA.
Courtney MaichakDepartment of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO, USA.
Lee JonesNatural Resource Program Center - Wildlife Health, United States Fish and Wildlife Service, Bozeman, MT, USA.
Sue VandeWoudeDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA.
Danielle E ButtkeBiological Resources Division, National Park Service, Fort Collins, CO, USA. Danielle_buttke@nps.gov.

Funding

Center of Excellence for Bison Studies 3TW049National Park Service P23AC01162-01
6 · The paper itself

Abstract

backgroundMycoplasmopsis (Mycoplasma) bovis is a significant pathogen in North American bison (Bison bison), causing severe disease with high morbidity and mortality. Effective serological diagnostics are essential for the surveillance and management of disease, yet commercially available ELISAs for M. bovis have only been developed for use in cattle and have not been validated in bison. In this study we evaluated a P48-based indirect ELISA for M. bovis detection and compared its diagnostic performance to a commercially available ELISA developed for use in cattle. Serum samples from bison were tested using both assays, and diagnostic metrics were assessed in comparison to infection status as confirmed by PCR and/or culture.

resultsThe commercial ELISA demonstrated superior sensitivity (77.8%) and specificity (98.0%) compared to the P48 ELISA (63.9% sensitivity, 94.9% specificity). Combining both ELISAs slightly improved sensitivity (83.3%) but did not significantly enhance overall diagnostic performance. Both the P48 and commercial ELISAs also exhibited cross-reactivity with other Mycoplasma species.

conclusionsWe identify significant challenges in serological diagnostics of M. bovis in bison with implications for interpretation of previous serological studies. Future research should focus on multiple immunogenic targets to enhance sensitivity and specificity for M. bovis serological surveillance.

Indexed as

BisonDiagnosticsDisease surveillanceELISAMycoplasmopsis (Mycoplasma) bovisSerology

Identifiers

PMID41530814
PMCPMC12933962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.